Ensemble Therapeutics Corporation

27 articles about Ensemble Therapeutics Corporation

• 

  BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor

  11/21/2023

  The biotech company has bought the global rights to an investigational oral CDK2 inhibitor from Ensem Therapeutics in a licensing agreement valued at up to $1.33 billion if all milestones are met.
• 

  Cambridge's Ensemble Therapeutics Quietly Shuts Down After 13 Years

  11/22/2017

  Ensemble Therapeutics has shut its doors for good, it seems.

• Ensemble Therapeutics Corporation Announces Global Pharma Partner Expands Access To IL-17 Assets

  5/25/2016

• Ensemble Therapeutics Corporation Achieves Milestone

  3/3/2016

• In High Demand: Ensemble Therapeutics Corporation Picks Novartis AG to Develop Oral, Mid-Sized Inflammation Drugs

  8/6/2013

• Roaring Alexion Pharmaceuticals Inc. Reaches Out to Ensemble Therapeutics Corporation to Fight Ultra-Rare Disorders

  7/18/2013

• Ensemble Therapeutics Corporation to Present Data on IL-17A Inhibitors that are Novel, Oral Macrocycles Against Previously Undruggable Target

  4/1/2013

• Ensemble Therapeutics Corporation Presents Oral Efficacy of First-in-Class Small Molecule Targeting IL-17 for Inflammation in Preclinical Studies

  11/12/2012

• Ensemble Therapeutics Corporation, Boehringer Ingelheim Corporation Ink $186 Milliion Macrocycle Drug Pact

  11/1/2012

• Ensemble Therapeutics Corporation to Present at 2012 American College of Rheumatology Annual Meeting

  10/29/2012

• Ensemble Therapeutics Corporation and Genentech Initiate Collaboration to Discover Macrocyclic Drug Candidates

  5/29/2012

• Ensemble Therapeutics Corporation Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb

  1/5/2012

• Ensemble Therapeutics Corporation Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

  1/5/2012

• Ensemble Therapeutics Corporation Receives Two Notices of Allowance for Fundamental Patents to DNA-Programmed Chemistry Process for Novel Macrocycle Therapeutics

  7/6/2011

• Ensemble Therapeutics Corporation Achieves Milestone in Bristol-Myers Squibb Company Collaboration

  4/12/2011

• Ensemble Therapeutics Corporation Appoints Ted Hibben as Senior Vice President, Corporate Development

  9/15/2010

• Ensemble Therapeutics Corporation Presents Data at American Chemical Society National Meeting

  8/24/2010

• Ensemble Discovery Corporation Initiates Collaboration with Pfizer Inc. (JOBS) to Develop Novel Drugs against Protein-Protein Interaction Targets

  1/6/2010

• Ensemble Discovery Corporation Initiates Collaboration with Bristol-Myers Squibb Company to Develop Drugs in Novel Therapeutic Class

  4/15/2009

• Ensemble Discovery Corporation And Roche Initiate Product Development Program to Advance New Diagnostic Technology to Optimize Cancer Therapy

  11/12/2008